Page last updated: 2024-10-25

ciglitazone and Compensatory Hyperinsulinemia

ciglitazone has been researched along with Compensatory Hyperinsulinemia in 1 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Compensatory Hyperinsulinemia: A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Petrie, J1
Small, M1
Connell, J1

Other Studies

1 other study available for ciglitazone and Compensatory Hyperinsulinemia

ArticleYear
"Glitazones", a prospect for non-insulin-dependent diabetes.
    Lancet (London, England), 1997, Jan-11, Volume: 349, Issue:9045

    Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc

1997